the warfarin and $10,195 (12,780) in the warfarin and NSAIDs groups (p < 0.01).

CONCLUSIONS: This analysis did not identify a difference in the odds of having a GI bleed when on warfarin or warfarin plus NSAIDs. Unexpectedly, there were significantly lower costs for the warfarin plus NSAIDs group. These results should be interpreted with caution due to the small sample size and limitations of retrospective analysis.

ADVERSE EVENTS OF PROMETHAZINE AND ONDANSETRON IN YOUNG CHILDREN AND WOMEN OF CHILD-BEARING AGE: A PHARMACOVIGILANCE STUDY BASED ON THE FDA ADVERSE EVENT REPORTING SYSTEM

Seidman LA1, Oto J2, Ayala FO2, Wigle P2
1 University of Cincinnati, Cincinnati, OH, USA, 2University of Cincinnati Medical Center, Cincinnati, OH, USA

OBJECTIVES: Pregnant women may use promethazine or ondansetron for nausea and vomiting during pregnancy (NVP). The long-term safety and its potential risks on the fetus and newborns are widely unknown. Promethazine has a black box warning for contraindicating its use in infants and young children. The purpose of this study was to quantity and describe adverse events (AEs) related to these two medications in child-bearing age women and young children. METHODS: The data source was the FDA's Adverse Events Reporting System database from 1997 to 2006. Using a retrospective data analysis, AEs for all patients with study drugs were compared to that for children ages 0-6 years old and women of child-bearing age (CBA) 15-50 years old. The annual frequencies of AEs for both study drugs were analyzed and stratified by age group and gender. The related AEs were categorized by clinical outcomes, pregnancy outcomes, route of administration, and duration of therapy. RESULTS: A total of 392,229 AEs for promethazine and 282,056 AEs for ondansetron were reported. Of those, 13.7% of ondansetron and 22% promethazine AEs were for CBA women with the peak for age 35-50, while 13.1% ondansetron and 13.8% promethazine AEs were for children age 0-6 with the peak for age 0-2. There were 23.6% and 13.5% AEs related to promethazine and ondansetron long-term use (greater than 90 days) among CBA women, respectively. The most common routes of administration were oral and intravenous. For CBA women, the frequent AE pregnancy outcomes were maternal complications (26%), premature labor (9%), maternal deaths affecting fetus (8%) and spontaneous abortion (4%), while the most frequent AEs for children were neonatal respiratory arrest (0.25%) and neonatal apnic attack (0.1%). CONCLUSIONS: AEs of promethazine and ondansetron among children and CBA women are common. The risk of their off-label use for the long-term treatment of NVP should be recommended with caution.

PREVALENCE, COSTS AND SERVICES OF COMORBID CONDITIONS ASSOCIATED WITH FUNCTIONAL DYSPEPSIA

Brook RA1, Talley NJ2, Choung RS3, Smeeding J4, Melkonian AK5, Kleinman NL6
1 The JeSTARx Group, Newfoundland, NJ, USA, 2Mayo Clinic Jacksonville, FL, Rochester, MN, USA, 3Procter & Gamble Company, Mason, OH, USA

OBJECTIVES: Women may use non-steroidal anti-inflammatory drugs (NSAIDs) or antiplatelet agents to prevent cardiovascular disease, compared to matched controls. The top MDC prevalence ratios between the FD cohort were greater than for controls in 155 (59%) of the 261 AHRQ’s Specific Categories and significantly greater (P < 0.05) in 76 categories (29%). Similarly, the services were greater for 179 (69%) of the 261 Specific Categories and significantly greater (P < 0.05) in 118 categories (44%). CONCLUSIONS: Th postseason showed excess comorbidity in employees with FD compared to employees without FD, might be a major determinant factors for excess health-care services and health-care costs of functional dyspepsia.

DE sway at study. 1The JeSTARx Group, Newfoundland, NJ, USA, 2Mayo Clinic Jacksonville, FL, Rochester, MN, USA, 3Procter & Gamble Company, Mason, OH, USA

OBJECTIVES: Women may use non-steroidal anti-inflammatory drugs (NSAIDs) or antiplatelet agents to prevent cardiovascular disease, compared to matched controls. The top MDC prevalence ratios between the FD cohort were greater than for controls in 155 (59%) of the 261 AHRQ’s Specific Categories and significantly greater (P < 0.05) in 76 categories (29%). Similarly, the services were greater for 179 (69%) of the 261 Specific Categories and significantly greater (P < 0.05) in 118 categories (44%). CONCLUSIONS: Th postseason showed excess comorbidity in employees with FD compared to employees without FD, might be a major determinant factors for excess health-care services and health-care costs of functional dyspepsia.

SYSTEMATIC REVIEW AND META-ANALYSIS OF PUBLISHED RANDOMIZED CONTROLLED TRIALS COMPARING THE EFFICACY OF PEGINTERFERON-ALPHA-2A VERSUS PEGINTERFERON ALPHA-2B PLUS RIBAVIRIN IN CHRONIC HEPATITIS C

Chinque H1, Barros MR1, Barros LG1, Santos E1, Buschini CT1
1Hospital das Clinicas da Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 2Hospital Portugues de Beneficencia em Pernambuco and Hospital das Clinicas - UFPE, Recife, Brazil, 3Rioche, Brazil, Sao Paulo, Brazil

OBJECTIVES: Hepatitis C affects approximately 180 million people worldwide. It is one of the main causes of liver disease and is the predominant etiology for liver transplantation. This study performs a systematic review and meta-analysis of published randomized controlled trials comparing efficacy of peginterferon-alpha-2a versus peginterferon-alpha-2b both in association with ribavirin in order to assess which is more effective in the treatment of HCV infection. METHODS: A thorough search in MEDLINE, Lilacs, Cochrane library and Embase databases was conducted in the last quarter of 2009. Manual searches in specialized websites were also carried out. Included studies were those which evaluated treatment efficacy of peginterferon-alpha-2a versus peginterferon alpha-2b both plus ribavirin for hepatitis C treatment in naive patients or nonresponders to other therapies not co-infected with HIV. According to heterogeneity test, a fixed or a random-effect models was adopted for meta-analysis. RESULTS: A total of 570 citations (databases citation without duplicates plus manual searches) were found but only seven met the inclusion criteria: 1) Ascione, 2009; 2) Rumi, 2009; 3) McHughston, 2006; 4) Venic, 2006; 5) Scotto, 2008; 6) Kolakoswka, 2008; 7) Berk, 2007. All studies are randomized controlled trials. There was a higher sustained virological response (SVR) as compared to peginterferon-alpha-2b: 51.7% versus 42.4% (RR = 1.23, IC 95% 1.10 – 1.38, assuming a fixed-effect model). For genotypes 1/4: 42.1% versus 33.3% (RR = 1.11, IC 95% 1.02 – 1.20, assuming a fixed-effect model) and for genotypes 2/3: 79.2% versus 73.8% (RR = 1.11, IC 95% 1.01-1.22, assuming a fixed-effect model). CONCLUSIONS: These findings suggest that peginterferon-alpha-2a is associated with a higher clinical response than peginterferon-alpha-2b indicating that it should be used as the standard-of-care therapy. Our results are in line with another recent published systematic review (Awad, 2009) which concluded that peginterferon-alpha-2a has a higher SVR as compared to peginterferon-alpha-2b, with similar safety profile.

A META-ANALYSIS OF THE 5-HT3 RECEPTOR ANTAGONISTS USE IN POST-OPERATIVE NAUSEA AND VOMITING PROPHYLAXIS

Tang D1, Malone DC2
1 University of Arizona, Tucson, AZ, USA, 2University of Arizona, College of Pharmacy, Tucson, AZ, USA

OBJECTIVES: To investigate whether the 5-HT3 receptor antagonists—ondansetron, granisetron, tropisetron, and dolasetron—used for the prevention of post-operative nausea and vomiting (PONV) differ in efficacy. METHODS: A meta-analysis was conducted using published studies. A systematic literature search within PubMed and the Cochrane Library for randomized, controlled, double-blinded studies measuring efficacy in terms of PONV prophylaxis was conducted. The odds of patients benefited from PONV and post-operative vomiting (PONV) within each study arm 24 hours after surgery were the primary indices of drug efficacy. Indirect comparisons using random effect models were conducted. Subgroup analyses excluding controversial studies and controlling amount of dose and administration route were also conducted. RESULTS: A total of 82 studies were identified, representing 15,709 patients. In terms of preventing PONV, the four antiemetic drugs had comparable efficacy: granisetron showed similar efficacy as compared to ondansetron (OR = 1.16, 95% confidence interval (CI): 1.09-1.22); ondansetron (OR = 1.15, 95%CI: 1.03-2.43); tropisetron (OR = 1.70, 95%CI: 0.95-0.35) and dolasetron (OR = 1.35, 95% CI: 0.78-2.27); ondansetron exhibited comparable efficacy as compared to tropisetron (OR = 1.06, 95% CI: 0.63-1.79) and dolasetron (OR = 0.84, 95%CI: 0.52-1.31); tropisetron and dolas- etron were also similar in efficacy (OR = 0.80, 95% CI: 0.44-1.37). Subgroup analyses also found that the four drugs did not differ in efficacy. All 5-HT3 receptor antagonists were statistically significantly better than placebo. CONCLUSIONS: With respect to PONV prophylaxis, granisetron was statistically significantly better than ondansetron and dolasetron; ondansetron, tropisetron, and dolasetron exhibit similar efficacy. With respect to PONV prophylaxis, ondansetron, granisetron, tropisetron, and dolasetron appeared to have comparable efficacy.

TEMPORAL CHANGES IN SURGICAL PROCEDURES FOR MANAGEMENT OF DIVERTICULAR DISEASE

Chambers, Knight, TK, Nichol PB
University of Southern California, Los Angeles, CA, USA

OBJECTIVES: Research has suggested that admissions for diverticular disease (DD) are on the rise in Western countries, particularly among a younger patient population. However, relatively little is known about how this increase has impacted the use of surgical procedures for the management of DD. The goals of this study were a) to determine temporal trends in the use of surgical procedures (laparoscopic colectomy [LC] and open colectomy [OC]) for DD, and b) to investigate temporal changes in...